| Name |
Doxorubicin hydrochloride |
| Brand name |
Adriamycin |
| Pharmaceutical Group |
Antineoplstics |
| Pharmaceutical chemical group |
Glycoside antracyclin |
| Mechanism of action |
DNA-binding and inhibition of DNA and RNA synthesis by disrupting the molecular structure and obstruct space, Induction of apoptosis |
| Indications |
Acute lymphocytic leukemia, acute myeloblastic leukemia, testicular interstitial cell carcinoma, ovarian, thyroid, Wilm's tumor, lungs (bronchial origin), gastric, head and neck, liver, cervix, prostate, endometrium, testis, lymphoma Hodgkin, soft tissue sarcoma and bone sarcoma |
| Intake |
Adults: 75-60 mg/m²/day- Administered intravenously |
| Indications |
Interference with concurrent use of allopurinol and colchicine, Concurrent use with daunorubicin increased risk of heart complications, Barbiturates, increase hepatic metabolism and reduce plasma drug levels, Streptozocin increase plasma levels of the drug, increase the risk of skin complications radiotherapy and intensity of hemorrhagic cystitis caused by cyclophosphamide, Concomitant use with other cytotoxic agents induced bone marrow complications |
|
